2026年欧洲肺癌大会（ELCC）将于当地时间3月25-28日在丹麦哥本哈根召开。作为肺癌领域备受瞩目的国际学术盛会之一，ELCC汇聚了全球肺癌诊疗的最新研究进展和成果。
目前，ELCC官网已披露部分摘要标题（LBA尚未公布），【肿瘤资讯】特此整理将在口头报告专场（Proffered Paper session）和迷你口头报告专场（Mini Oral session）公布的重磅研究进展。
口头报告专场1
日期：25.03.2026（星期三）
当地时间：16:45-18:15
地点：Auditorium A1
摘要号：1O
Efficacy and safety of setidegrasib in patients with advanced NSCLC with KRAS G12D mutation
Setidegrasib治疗KRAS G12D突变晚期NSCLC患者的疗效与安全性
讲者：Luis Paz-Ares (Madrid, Spain)
摘要号：2O
Osimertinib (osi) with or without chemotherapy (CTx) as first-line treatment in EGFR-mutant (EGFRm) advanced NSCLC with concurrent TP53 mutations (TOP study)
奥希替尼（osi）联合或不联合化疗（CTx）作为EGFR突变（EGFRm）晚期NSCLC合并TP53突变患者的一线治疗（TOP研究）
讲者：杨云鹏 中山大学肿瘤防治中心
摘要号：408O
Phase II Study of iza-bren (BL-B01D1) in Combination with Serplulimab in Patients with Small Cell Lung Cancer (SCLC)
iza-bren（BL-B01D1）联合斯鲁利单抗治疗小细胞肺癌（SCLC）的II期研究
讲者：周斐 同济大学附属东方医院
摘要号：409O
409O - A phase I dose escalation trial of obrixtamig + ezabenlimab in patients (pts) with small cell lung cancer (SCLC) or other neuroendocrine carcinomas (NECs) expressing DLL3
Obrixtamig联合ezabenlimab治疗表达DLL3的小细胞肺癌（SCLC）或其他神经内分泌癌（NECs）患者的I期剂量递增试验
讲者：Julien Mazieres (Toulouse, France)
迷你口头报告专场1
日期：26.03.2026（星期四）
当地时间：16:00-17:15
地点：Auditorium A1
摘要号：4MO
Updated results for MK-1084 + pembrolizumab in KRAS G12C-mutated (mut) metastatic non–small-cell lung cancer (mNSCLC) enrolled in KANDLELIT-001
KANDLELIT-001研究中MK-1084联合帕博利珠单抗治疗KRAS G12C突变转移性非小细胞肺癌（mNSCLC）的更新结果
讲者：Adrian G. Sacher (Toronto, Canada)
摘要号：5MO
Phase II ETOP ADEPPT trial: Adagrasib in patients with KRASG12C-mutant NSCLC who are elderly or have poor performance status - Final results
ETOP ADEPPT II期试验：Adagrasib治疗老年或体能状态差的KRAS G12C突变NSCLC患者——最终结果
讲者：Jarushka Naidoo (Dublin, Ireland)
摘要号：221MO
Stereotactic body radiotherapy (SBRT) followed by durvalumab in early-stage non-small-cell lung cancer (NSCLC) patients – results from a randomized phase II trial (ASTEROID)
早期非小细胞肺癌（NSCLC）患者立体定向放疗（SBRT）联合度伐利尤单抗——随机II期试验ASTEROID结果
讲者：Andreas Hallqvist (Göteborg, Sweden)
摘要号：6MO
Zongertinib in treatment-naïve patients with HER2-mutant NSCLC, including those with active brain metastases: Beamion LUNG-1
宗艾替尼治疗初治HER2突变NSCLC患者（包括活动性脑转移患者）：Beamion LUNG-1研究
讲者：John Heymach (Houston, United States of America)
摘要号：7MO
Becotarug (JMT101) and Osimertinib (Osi) in Patients (pts) with Platinum-Pretreated EGFR Exon 20 Insertion-Mutated (ex20ins) Non-Small Cell Lung Cancer (NSCLC): Final Overall Survival (OS) and Subgroup Analyses from the BECOME Phase 2 Study
Becotarug（JMT101）联合奥希替尼（Osi）治疗铂类经治EGFR 20外显子插入突变（ex20ins）非小细胞肺癌（NSCLC）患者：BECOME II期研究的最终总生存期（OS）及亚组分析
讲者：张力 中山大学肿瘤防治中心
迷你口头报告专场2
日期：27.03.2026（星期五）
当地时间：08:15 - 09:45
地点：Auditorium A1
摘要号：222MO
Exploratory Analysis of Participants Without Pathological Complete Response (pCR) in the KEYNOTE-671 Study of Perioperative Pembrolizumab (Pembro) in Early-Stage NSCLC After 5 Years of Follow-Up
KEYNOTE-671研究中围手术期帕博利珠单抗（Pembro）治疗5年随访后未达到病理完全缓解（pCR）的早期NSCLC患者的探索性分析
讲者：Martin Reck (Grosshansdorf, Germany)
摘要号：223MO
Five-Year Outcomes of Participants With Pathological Complete Response (pCR) Enrolled in the KEYNOTE-671 Trial of Perioperative Pembrolizumab (Pembro) in Early-Stage NSCLC
KEYNOTE-671试验中病理完全缓解（pCR）早期NSCLC患者围手术期帕博利珠单抗（Pembro）治疗的5年结局
讲者：Margarita Majem (Barcelona, Spain)
摘要号：8MO
Subcutaneous Versus Intravenous Toripalimab, in Combination with Chemotherapy, as a First-Line Treatment for Recurrent or Metastatic Non-Squamous (Nsq) Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase 3 Trial
皮下注射与静脉注射特瑞普利单抗联合化疗作为复发或转移性非鳞状（Nsq）非小细胞肺癌（NSCLC）一线治疗的随机III期试验
讲者：邬麟 湖南省肿瘤医院
摘要号：500MO
PD-L1 Blueprint AI: Validation of an AI-assisted PD-L1 scoring algorithm against original Blueprint Study data
PD-L1 Blueprint AI：AI辅助PD-L1评分算法与原始Blueprint研究数据的验证
讲者：Fred R. Hirsch (New York, CO, United States of America)
摘要号：9MO
A first-in-human phase I study of TQB2922, an EGFR/C-MET bispecific antibody, as monotherapy and in combination with bevacizumab and chemotherapy in EGFR-mutant non-small cell lung cancer
TQB2922（EGFR/C-MET双特异性抗体）单药及联合贝伐珠单抗和化疗治疗EGFR突变非小细胞肺癌的首次人体I期研究
讲者：薛锦慧 中山大学肿瘤防治中心
摘要号：10MO
SHR-A2009, a HER3-targeted ADC, plus aumolertinib (A) as 1L or ≥2L treatment for EGFR-mutated (EGFRm) NSCLC: a phase 1b/2 study
SHR-A2009（HER3靶向ADC）联合阿美替尼（A）作为EGFR突变（EGFRm）NSCLC一线或二线及以上治疗：一项1b/2期研究
讲者：吴一龙 广东省人民医院
摘要号：11MO
First disclosure of efficacy and safety data for YL202/BNT326 (HER3 ADC) from a Phase 2 trial in patients (pts) with non-small cell lung cancer (NSCLC)
YL202/BNT326（HER3 ADC）治疗非小细胞肺癌（NSCLC）患者II期试验疗效和安全性数据的首次披露
讲者：刘海峰 吉林省肿瘤医院
口头报告专场2
日期：27.03.2026（星期五）
当地时间：14:45 - 16:15
地点：Auditorium A1
摘要号：3O
Anti-Tumor Activity of Gotistobart Compared to Docetaxel in Patients with Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) Progressing on PD-(L)1 Inhibitors: Stage 1 PRESERVE-003 Phase 3 Trial
Gotistobart对比多西他赛治疗PD-(L)1抑制剂治疗进展后转移性鳞状非小细胞肺癌（sqNSCLC）患者的抗肿瘤活性：PRESERVE-003 III期试验第一阶段
讲者：Kai He (Columbus, United States of America)
尚有约5项LBA未公布标题，您还期待哪些重磅进展？持续关注2026 ELCC！
扫描二维码，获取更多ELCC 2026专栏资讯！
排版编辑：肿瘤资讯-TY
苏公网安备32059002004080号
